RBC Capital Maintains Outperform Rating on Xylem, Cuts Target to $135
RBC Capital maintained its Outperform rating on Xylem and cut its price target to $135 per share from $164.
RBC Capital maintained its Outperform rating on Xylem and cut its price target to $135 per share from $164.